Introduction
Protein tyrosine kinases (PTKs) regulate proliferation, differentiation and cellular responses to a variety of external stimuli by binding and recruiting adaptor/ effector molecules (Neet and Hunter, 1996; Schlessinger, 2000) . PTKs function by phosphorylating protein substrates on tyrosine residues, a dynamic event that is opposed by the action of protein tyrosine phosphatases (Fischer et al., 1991; Avraham et al., 2000) . For example, activation of either receptor or nonreceptor PTKs (NRPTKs) can trigger the activation or inactivation of immediate downstream signaling components involved in regulating p21 Ras, a small GTPase (Erpel and Courtneidge, 1995; Marte and Downward, 1997; Sun et al., 2000) . The activation of p21 Ras and subsequent downstream signal transduction is initiated at the plasma membrane as a result of association with adaptor molecules like Grb2 and guanine nucleotide exchange factors like Sos1/2 (Egan et al., 1993; Aronheim et al., 1994; Leevers et al., 1994) . This results in direct binding and activation of Raf1, a serine/ threonine protein kinase that leads to the activation of mitogen-activated protein kinases (MAPKs) (Kinoshita et al., 1995) or other members of the Ras superfamily including Rho, Cdc 42 and Rac (Nobes and Hall, 1995; Sun et al., 2000; Sahai and Marshall, 2002) . Activated GTP-bound Ras is inactivated by intrinsic GTPase activity with hydrolysis of the nucleotide g-phosphate, which can be stimulated by GTPase-activating proteins (GAPs). Point mutations in wt-Ras are known to reduce dramatically its intrinsic Ras GTPase activity imparting oncogenic phenotype to cells (Gibbs et al., 1984; Manne et al., 1985) . Interestingly, the phenotype induced by oncogenic Ras has been reported to be reversed by Rap1A, a small GTPase of the Ras superfamily, indicating that even constitutive Ras activity can be blocked by cellular regulation (Kitayama et al., 1989; Bos, 1998) . While much is understood at the molecular and biochemical level about how NRPTK may activate Ras, a role for NRPTKs in negative regulation of Ras is not clear.
Murine embryonic stem (ES) cells are pluripotent, being capable of both self-renewal and differentiation with the formation of multiple cell types and tissues (Evans and Kaufman, 1981; Wiles and Keller, 1991) . ES cells can be maintained in an undifferentiated state by culturing on an embryonic fibroblast feeder layer or in the presence of leukemia inhibitory factor (LIF) (Martin, 1981; Wiles and Keller, 1991) . Differentiation of ES cells into embryoid bodies occurs in vitro upon removal of LIF from the cultures (Evans and Kaufman, 1981; Martin, 1981; Smith et al., 1988; William et al., 1988; Schmitt et al., 1991; Wiles and Keller, 1991) . Therefore, ES cells are an attractive and useful model to study the cellular and molecular mechanisms that may regulate these developmental events, including Ras signaling. For example, one of the initial events that occurs after 3 days following LIF withdrawal is the formation of multipotential hematopoietic progenitor cells (HPC) characterized by CFU GEMM activity (Hole et al., 1996) . The pathways activated by LIF withdrawal that are involved in early HPC development are known to involve the well-described Ras-Raf1-MAPK pathway that stimulates proliferation (Amrein et al., 1992; Stahl et al., 1995; Ernst et al., 1996; Nakano et al., 1996; Yamane et al., 1997; Neubauer et al.,1998; Parganas et al., 1998) . We sought to identify novel tyrosine kinases that may be involved in regulating early hematopoiesis during ES cell differentiation by screening murine D3ES cells following LIF withdrawal for 3 days, a time by which we could first detect CFU GEMM colonies that develop in vitro (data not shown). One such novel PTK, kinase of embryonic stem cells (Kos1) that lacked a putative transmembrane domain was identified. Studies reported here indicate that Kos1 is a novel NRPTK that may negatively regulate cell growth by indirectly inhibiting Ras activity.
Results

Kos1 is a novel nonreceptor protein tyrosine kinase
Multipotential murine hematopoietic progenitors can be identified in murine ES cells by d3 following LIF withdrawal (Hole et al., 1996) . A cDNA library was constructed from d3 D3ES cells and screened using the degenerate PCR approach (Wilks, 1989) . The PCR Figure 1 (a) Primary amino-acid sequence of Kos1. The arrows show the kinase domain of Kos1. The putative, conserved ATPbinding site in kinase subdomains I and II are represented by GxGxxG and VAVK sequences shown in bold and italic. Catalytically inactive Kos1 was made by replacing lysine (K 148 ) with alanine (A) in VAVK, and is underlined. The tyrosine kinase insert region initially amplified by PCR from d3 D3ES cells following LIF withdrawal is in bold and underlined, while the WCAPES motif in the kinase insert and found in the conserved tyrosine kinase subdomain VIII is in italic. The asterisk sign (*) denotes the four potential tyrosine phosphorylation sites. The putative tyrosine-based endocytic motif YxxIL (aa 23-27) is double underlined. The sequence encompassing the immunoreceptor tyrosine activation motif (ITAM), YxxGx 7 YxxL (aa 66-80), is in bold. The two minimal phosphotyrosine-binding motif (PTB), NxxY, are indicated with broken line while the two tandem SH3-binding motif, (PxxP), present in the unique C-terminal are boxed (x represents any amino acid). (b) Organization of murine Kos gene. Two identical genomic clones (B8.5 kb) obtained from murine genomic BAC library were subcloned and sequenced to establish the intron-exon boundaries. The exons are represented in solid boxes and numbered I-VIII. The solid boxes in Kos1 cDNA represents the exons constituting the ORF with the translation start (ATG) and the termination (TGA) sites, shown by arrows. The exons I and II are noncoding. The catalytic domain (exons IV-VIII) is boxed in Kos1 cDNA. The tyrosine phosphorylation sites in the extra-catalytic domain are indicated as P Kos1 (kinase of stem cells), a negative regulator of cell growth K Hoare et al strategy uses degenerate oligonucleotide primers corresponding to the conserved tyrosine kinase motifs VHRDLA and SDVWSYG that flank the unique tyrosine kinase insert regions present within the catalytic domain of all PTKs. The specifically amplified B210 bp inserts were cloned and sequenced. Of the 125 inserts obtained, one was unique. The remaining 124 clones were represented by previously identified PTKs including Jak1, Jak2, Jak3, c-Kit, c-Fes, Fak, EGFR and PDGFR. The unique insert was used to perform 5 0 and 3 0 rapid amplification of cDNA ends (RACE) and a 1.82 kb cDNA was obtained that contained the entire open reading frame (ORF) of a novel PTK, Kos1. The Kos1 ORF is 1302 bp and predicts a B47 kDa protein product.
Analysis of the primary sequence of Kos1 indicates the presence of all 12-conserved structural tyrosine kinase subdomains characteristic of PTKs, including a WCAPES motif (Figure 1a ; Hanks et al., 1988; Hanks and Hunter, 1995) . However, the Kos1 sequence does not contain a putative transmembrane domain, suggesting that Kos1 is a cytosolic NRPTK. Kos1 contains four putative tyrosine phosphorylation sites, three in the Nterminal domain (Y23, Y66 and Y77) and one in the Cterminal domain (Y388; Figure 1a) . The presence of a tyrosine-based endocytic motif YxxIL (aa 23-27) suggests a potential role for Kos1 in the cellular process of endocytosis (Haucke and De Camilli, 1999) . In addition, the presence of a YxxGx 7 YxxL motif (aa 66-80) N-terminal to the kinase domain resembles a putative immunoreceptor tyrosine-based activation motif (ITAM) consensus sequence, YxxI/Lx 7/8 YxxI/L (Reth, 1989; Isakov et al., 1995) , suggesting a potential for interaction with SH2-containing protein(s). Both the N-and C-terminal extra catalytic domains of Kos1 contain NxxY motifs, suggesting a potential interaction with a phosphotyrosine-binding domain (PTB) containing protein(s) (Weiss, 1993; Kavanaugh and Williams, 1994; Kavanaugh et al., 1995; Laminet et al., 1996) . In addition, the C-terminal extracatalytic domain contains two tandem PxxP motifs, suggesting the potential to bind SH3-containing proteins (Cohen et al., 1995) . The presence of an ITAM in Kos1 distinguishes it from other PTKs. Thus, Kos1 potentially may participate in multiple functional interactions.
Kos1 is homologous to three other nonreceptor protein tyrosine kinases, Tnk1 (90% identical, 92% conserved; Hoehn et al., 1996) , Ack1 and Ack2 (43% identical, 58% conserved; Manser et al., 1993; Yang and Cerione, 1997) . Interestingly, the homology between Kos1, Tnk1 and the Acks exists only for the N-terminal of Kos1 (aa 1-380) that includes the N-terminal extracatalytic and the kinase domain, but is completely divergent in the C-terminal 54 amino acids (Figure 1a ). This feature suggests that Kos1 may function differently from Tnk1 and the Acks.
Identification of Kos1
An SV129 mouse genomic bacterial artificial chromosome (BAC) library was screened using the full-length Kos1 cDNA as probe (Genome Systems). Two genomic clones of B8.5 kb were obtained and found to be identical by sequencing. The exon nucleotide sequence of the clones was identical to the Kos1 cDNA obtained by RACE and thereby verified its genetic integrity. The Kos1 sequences have been submitted to the GenBank databases (Accession numbers AF307745 and AF307746). Kos1 spans approximately 4.3 kb of genomic structure and contains eight exons (Figure 1b) . The first two exons are noncoding while exon III contains the ATG translational initiation codon. The predicted kinase domain is present between exons IV and VIII (aa 123-380).
Chromosomal localization of Kos1
Kos1 was localized to the middle region of mouse chromosome 11 by interspecific backcross mapping (Copeland and Jenkins, 1991) using full-length Kos1 cDNA as well as the unique 153 bp Kos1 fragment that corresponds to the C-terminal extracatalytic 54 amino acids of Kos1. This region of mouse chromosome 11 corresponds to human chromosome 17p13.1 locus where Tnk1 also maps (Hoehn et al., 1996) . Therefore, we propose that murine Kos1 and human Tnk1 represent splice variants of the same gene.
Kos1 is developmentally regulated and ubiquitiously expressed
Since Kos1 was identified in murine ES cells following LIF removal to induce embryoid body differentiation, Kos1 mRNA expression was initially examined in developing mouse embryos. A commercial mouse embryo polyA + RNA blot (Clontech) was probed using the full-length Kos1 cDNA. A B2.0 kb Kos1 transcript was found to be upregulated between E7 and E11 (Figure 2a ), following which Kos1 was downregulated to a steady-state level of expression by E17 that was maintained during the remainder of embryogenesis. Interestingly, both E13 and E17 samples show an additional lower-sized transcript of B1.6 kb, but its significance is not clear. Stripping and rehybridizing the same filter with either a unique 153 bp 3 0 or a 230 bp 5 0 Kos1 probe demonstrated that only the B2.0 kb transcript is detected (data not shown). This indicates that the smaller B1.6 kb band may either be an unrelated product or possibly related to a common kinase domain-containing region present in other PTKs.
To assess Kos1 expression in adult tissues, a ribonuclease protection assay (RPA) was developed. Both 5 0 and 3 0 Kos1 probes were used to ensure specific identification of the authentic Kos1 mRNA. A 280 bp 5 0 Kos1 probe protected a 230 bp fragment that could represent the 'common' N-terminal extracatalytic region of both Kos1 and Tnk1. However, a 180 bp 3 0 Kos1 probe protected only a unique C-terminal extracatalytic 153 bp fragment of Kos1, confirming the ubiquitous expression of full-length Kos1 in adult tissues ( Figure 2b) . As a control, RPA reactions were simultaneously carried out with a 150 bp actin probe that protected a 125 bp actin mRNA fragment (Figure 2c ). Kos1 mRNA expression was identified in virtually all mouse tissues examined including the liver, kidney, heart, brain, skeletal muscle and intestine, as well as in a positive control sample from d3 D3ES cells. Collectively, these findings indicate that Kos1 is expressed ubiquitously in adult tissues.
A peptide that represents the unique C-terminal extracatalytic domain of Kos1 (aa 380-393) was synthesized and used to produce a specific rabbit Kos1 antiserum as described. The antiserum can detect a 47-kDa protein expressed in D3ES cells and is specifically (a) D3ES cells were grown in the presence of LIF followed by withdrawal of LIF from the culture medium (0, 3, 7 and 15 days). Cells lysates were prepared and 50 mg protein from each sample were resolved by SDS-PAGE (10%) and transferred onto nitrocellulose paper. The blot was probed with rabbit Kos1 antiserum raised against a synthetic peptide located in the unique C-terminal domain of Kos1. (b) Peptide competition of the Kos1 protein bands with excess synthetic peptide against which the antiserum was raised Kos1 (kinase of stem cells), a negative regulator of cell growth K Hoare et al competed using the peptide against which the antiserum was raised (Figure 3a and b) . These data indicate that Kos1 is upregulated in D3ES cells at d3 following LIF withdrawal and declines to a lower, steady-state level of expression by d15 in vitro. This dynamic pattern of Kos1 expression in vitro mimics that observed for Kos1 expression in the developing embryo (Figure 2a) . Results also indicate that Kos1 is expressed in most adult mouse tissues examined with the possible exception of the lung (Figure 4a ). Kos1 is also detected in various murine and human myeloid-and lymphoidderived cell lines (Figure 4b and c), confirming its ubiquitous expression.
Subcellular localization of Kos1
Kos1 is predicted to be an NRPTK based on its lack of a putative hydrophobic transmembrane domain (Neet and Hunter, 1996) . Murine M1 leukemia cells were subjected to subcellular fractionation to isolate the heavy membrane (H; mitochondrial membrane), light membrane (L; plasma membrane), cytosol (C) and nuclear membrane (N) fractions. Western blot analysis of these fractions demonstrates that Kos1 is localized predominantly in the cytosol (Figure 5a and b). The purity of the subcellular fractionations is indicated by the detection of Grb2, a cytosolic protein that interacts with plasma membrane regulators and adaptor molecules, in the cytosol and light membrane fractions ( Figure 5c ).
To verify the subcellular localization of Kos1 in situ, GFP or GFP-Kos1 constructs were transiently expressed in Cos7 cells. Cells were stained with Hoechst 33342 dye to identify nuclei and examined using a fluorescence microscope. Results confirm that GFPKos1 is cytoplasmic since green fluorescence is observed only in the cytoplasm but not in the nucleus (Figure 5e ). Importantly, the GFP-only expressing cells exhibit diffuse distribution pattern of green fluorescence within the cell, indicating that GFP does not likely influence the intracellular localization of Kos1 (Figure 5d ).
Kos1 contains autotyrosine kinase activity
To determine whether Kos1 possesses intrinsic tyrosine kinase activity as predicted from the primary sequence ( Figure 1a ), a catalytically null Kos1 mutant, Kos1(CN), and a truncated Kos1 (DKos) were created and compared to Kos1 for tyrosine kinase activity. The Kos1(CN) mutant was engineered to contain a singlesite mutation at lysine 148 (K148A) in the putative ATPbinding site located in kinase subdomain II ( Figure 1a ). Creating this point mutation is a frequently used strategy to abrogate kinase activity of PTKs (Hanks and Hunter, 1995; Johnson et al., 1996) . DKos was created by deleting the unique C-terminal domain of Kos1 by utilizing a convenient restriction site to test the functional significance of the C-terminal domain. The GFP-Kos constructs were transiently transfected alone or cotransfected with the GFP-Kos1(CN) in Cos7 cells to test whether Kos1 is an autotyrosine kinase. After 48 h, cells were metabolically labeled with 32 P-orthophosphoric acid and lysed in modified RIPA buffer. The GFP fusion proteins were immunoprecipitated using a The same filter after stripping was immunoblotted with a mouse monoclonal a-GFP antibody Kos1 (kinase of stem cells), a negative regulator of cell growth K Hoare et al rabbit anti-GFP antibody and the protein bands were resolved by electrophoresis and transferred on to a nitrocellulose membrane that was exposed to X-ray film. The membrane was also immunoblotted with a specific phosphotyrosine antibody, Py20, or an anti-GFP antibody. Results indicate that both GFP-Kos1 and GFPDKos are 32 P-labeled on a tyrosine residue(s) since identical metabolically labeled bands are detected by Py20 (Figure 6 ). Thus, GFP-Kos1 and GFP-DKos possess intrinsic tyrosine kinase activity and can be autophosphorylated. In addition, the C-terminal domain of Kos1 apparently does not affect its autokinase activity (Figure 6a and b) . In contrast, GFP-Kos1(CN) failed to undergo tyrosine phosphorylation when expressed alone, indicating the potential absence of intrinsic tyrosine kinase activity. However, when the GFP-Kos1(CN) is cotransfected with either GFP-Kos1 or GFP-DKos, GFP-Kos1(CN) is tyrosine phosphorylated indicating that catalytically active GFP-Kos1 can transphosphorylate the catalytically inactive GFPKos1(CN). Collectively, these data indicate that Kos1 has intrinsic autotyrosine kinase activity and that other potential substrate(s) for Kos1 may also exist.
Autokinase activity of Kos1 is required for inhibition of cell growth
The expression of Kos1 was initially examined following IL3 withdrawal from murine factor-dependent myeloid NFS/N1.H7 (H7) cells. H7 cells are exquisitely sensitive to factor deprivation with more than 50% of the cells undergoing apoptosis by 24 h. Interestingly, Kos1 expression is also significantly increased at this time, while Erk2 (MAPK) expression is decreased (Figure 7 ). This reciprocal relation indicates that Kos1 upregulation is specific. Importantly, upregulation occurs between 2 and 12 h, a time that precedes apoptosis, suggesting that Kos1 may function as a negative regulator of cell growth. This notion was tested by stably expressing HA-tagged Kos1 or kinase-dead Kos1(CN) in NIH 3T3 cells. We observed that higher level expression of exogenous Kos1 prevents cell growth and survival such that we could only isolate clones that stably express relatively lower levels of Kos1 (Figure 8a ). The stability of Kos1 expression in the clones was assessed by demonstrating stable expression over 10 passages. Functionally, both Kos1-and Kos1(CN)-expressing cells exhibit significant changes in morphology when compared to vector-alone transfected cells (Figure 8b) . A branching/spiking-like cell morphology is observed in the cells, similar to that observed for cells overexpressing the related family member, Ack2. Interestingly, Ack2 also has been reported to inhibit cell growth . We found that forced expression of Kos1 also results in significant inhibition of cell growth (Figure 8c ). By contrast, kinase-dead Kos1(CN) mutant profoundly enhances cell growth, indicating a necessary and sufficient role for Kos1's intrinsic autotyrosine kinase activity in inhibiting cell growth.
We next determined the effect of Kos1 or Kos1(CN) expression on growth rate compared to that of vectoronly transfected cells (Figure 8d ). The results indicate that the cells overexpressing Kos1 demonstrate a reduced growth rate compared to those expressing the kinase-dead Kos1(CN) mutant. Since Kos1 is upregulated in H7 cells following the stress of IL3 withdrawal, which inhibits cell growth and eventually results in cell death (Figure 7 ), we assessed a role for Kos1 under the stress of reduced serum, (0.5%), in the growth medium. Interestingly, the Kos1-expressing clones show complete growth arrest, while both the kinase-dead Kos1(CN)-expressing cells and the vector-only transfected cells continue to grow. However, the Kos1(CN)-expressing cells grew at a significantly higher rate (Figure 8c and d) . These data strongly suggest that Kos1 functions as a negative regulator of cell growth and may be upregulated before or during apoptosis in association with growth inhibition. We next examined the effect of Kos1 expression on cell growth in soft agar to assess its effect on anchorage-independent growth (Figure 8e ). While the Kos1-expressing cells fail to grow, the Kos1(CN) clones demonstrate clear anchorage-independent growth with a colony-forming efficiency of 57% (Yang et al., 1998; Barradas et al., 1999) . These findings suggest that Kos1 may have tumor suppressor properties.
Kos1 autokinase activity is required to suppress Ras activity
To determine potentially the mechanism by which Kos1 may function as a negative regulator of growth, we tested whether Kos1 may affect the Ras-Raf1-MAPK pathway, since p21 Ras is a promoter of cell growth (Okuda et al., 1994) . Therefore, a functional assay for Kos1 was designed to assess whether it can affect Ras GTPase activity by determining the amount of GTPbound Ras in vivo. We reasoned that if Kos1 affected GTP-bound Ras, then the effect could be reflected on the level of Raf1 and MAPK activities. Cos7 cells were transiently cotransfected with wt-Ras and either GFP-D-Kos, GFP-Kos1, GFP-Kos1(CN) or GFP alone as control. After 48 h, the cells were harvested and lysed in lysis buffer. The GTP-bound Ras was quantified in the clarified cell lysates using a commercially available Raf1 RBD-agarose assay as described in Materials and methods. The Raf1 kinase and MAPK activities were simultaneously determined, respectively, by using an immunocomplex kinase assay with GST-MEK1 as the Raf1 substrate and a specific phospho-Erk1/2 antibody to detect activated Erks. The expression level of Ras, Erk1/2, the GFP/GFP-fusion proteins and actin were assessed ( Figure 9 ). Results indicate that while increased expression of GTP-bound Ras (B2.4-fold) occurs in cells coexpressing wt-Ras and GFP, the level of GTPbound Ras was significantly reduced (B1.2-fold) in cells coexpressing wt-Ras and GFP-DKos1 or GFP-Kos1 (Figure 9 ). In contrast, cells expressing both wt-Ras and GFP-Kos1(CN) showed increased levels of GTP-bound Ras (B3.0 fold) as well as increased Raf1 and MAPK activities. These data support the hypothesis that Kos1 negatively regulates Ras and inhibits the Ras-Raf1-MAPK pathway. Furthermore, results indicate that Kos1 suppresses Ras by a mechanism that requires the intrinsic autokinase activity of Kos1, although we have been unable to demonstrate a direct interaction between (CN) . (e) Kos1(CN) induces anchorage-independent growth. Soft agar assays were carried out as described in Materials and methods. Cells expressing HA Kos1, HA Kos1(CN) and vector control were seeded in 35 mm plate (7.5 Â 10 3 cells per plate) and the growth was monitored. After 15 days, the number of colonies formed were counted and compared with the number of cells seeded Kos1 (kinase of stem cells), a negative regulator of cell growth K Hoare et al Kos1 and wt-Ras. Therefore, we conclude that Kos1 negatively regulates p21Ras activity by an indirect mechanism.
Forced expression of Kos1 inhibits oncogenic Ha-Ras(G12V)-induced growth of NCI-H82 cells Kos1 inhibits Ras activity (Figure 9 ). To address whether Kos1 can also inhibit oncogenic Ras(G12V) activity, human lung cancer NCI-H82 cells that stably express oncogenic Ha-Ras(G12V) were transfected with either GFP-Kos1 or GFP. Two stably expressing GFPKos1 clones were selected for further testing. No significant aberrant growth characteristics were noted when the cells were grown in the presence of 10% fetal bovine serum. However, when the serum concentration was reduced to 0.5%, a significantly aberrant growth pattern of GFP-Kos1-expressing cells is observed (Figure 10a ). The GFP-Kos1-expressing cells grow more slowly than control cells and the clone expressing the highest level of GFP-Kos1 (clone 1) grew even more slowly than the clone expressing the lower level of GFPKos1 (clone 2; Figure 10a and b). These results are consistent with a dosage effect for Kos1 on growth inhibition under the stress conditions of reduced serum. It is interesting to note that Kos1 expression does not inhibit growth of the oncogenic Ras(G12V) transformed cells in 10% serum. While the reason for this is not clear, it may result from the potent oncogenic Ras activity being able to over-ride the growth inhibitory effect of Kos1 when the serum concentration is high but not under a low concentration that represents a form of stress.
Kos1 suppresses oncogenic Ha-Ras(G12V), Raf1 and Erk2 (MAPK) activities
To assess how GFP-Kos1 may interfere with oncogenic Ras(G12V) transformation of NCI-H82, total Ras- Figure 9 Kos1 tyrosine kinase activity is required to inhibit p21Ras activity. Cos7 cells (2 Â 10 5 ) were transiently transfected with GFP alone or cotransfected with wt-Ras and either GFP, GFP-DKos (truncated Kos1), GFP-Kos1 (wt-Kos1) or GFPKos1(CN) (catalytically null Kos1). The levels of in vivo GTPbound Ras pulled down with Raf1 RBD-agarose were determined as described in Materials and methods. Cell lysates containing 100 mg protein were analysed by immunoblotting using a-Ras, aphosphoErks, a-Erk2, a-GFP and a-actin antibodies. Raf1 kinase activity in the cell lysates was determined by immunocomplex kinase assay using MEK1 as the substrate as described in Materials and methods. Similar results were obtained from three independent experiments GTPase activity of the two clones and control cells was measured following growth in reduced serum conditions (0.5%). The level of GDP-and GTP-bound HaRas(G12V) was determined and the GDP:(GTP+GDP) ratio calculated. The ratios for clones 1 and 2 were found to be 2-5 fold higher compared to the GFP-only control cells (Figure 11a ). This indicates that Kos1 may potentially suppress oncogenic Ras activity under the stress of serum starvation as discussed above. Further, the Ha-Ras(G12V) bound-GDP level in clone 1 is B2.5-fold higher than that for clone 2, indicating that suppression of oncogenic Ras activity under serum starvation conditions closely correlates with GFP-Kos1 expression levels (Figure 10b ). Interestingly, increased expression of Rap1A, a small GTPase of the Ras superfamily that can suppress oncogenic Ras, was found to be induced in the GFP-Kos1-expressing cells but not in GFP-expressing control cells, under reduced serum conditions (Figure 11b ). This finding raise the possibility that Kos1-mediated suppression of oncogenic Ras under the stress of serum starvation may potentially involve Rap1A. However, further studies will be required to test this possibility. Since we have been unable to detect a direct interaction between Kos1 and Ha-Ras(G12V), we suspect that Kos1 may suppress Ha-Ras (G12V) activity by an indirect mechanism. Ras transduces its biochemical signals by recruiting and activating effector molecules at the inner surface of the plasma membrane, including Raf1, in order to stimulate the downstream MAP kinase growth pathway (Erpel and Courtneigde, 1995) . We tested whether the inhibition of oncogenic Ras(G12V) activity by Kos1 under low serum conditions may also affect Raf1-MAP kinase activity. Results reveal that Raf1 activity is Figure 11 Kos1 suppresses oncogenic Ras(G12V) activity in NCI-H82: Ha-Ras(G12V) cells under reduced serum conditions. The 32 Plabeled GDP and GTP bound to Ras was immunoprecipitated from NCI-H82: Ha-Ras(G12V) cells expressing either GFP or GFPKos1 (clones 1 and 2) with a-Ras-proteinG-agarose complex (T), while mock precipitation was performed with proteinG-agarose (C) as described in Materials and methods. The bound guanine nucleotides eluted from the proteinG-agarose complex were fractionated by TLC and quantitated by Instant Imager (Packard). The specific GDP/(GDP+GTP) ratio for bound oncogenic Ras(G12V) was determined as described. (b) Western blot analysis for the expression of Rap1A and Erk2 in both clones with anti-Rap1A and antiErk2 antibodies Figure 12 Downregulation of Raf1 (a) and MAPK (Erk2); (b) activities in NCI-H82: Ha-Ras(G12V) cells expressing GFP-Kos1 relative to the control cells expressing GFP, under reduced serum conditions. The inset in each panel shows the intensities of the reduced by 60 and 35%, while the Erk2 activity was reduced by 35 and 15%, in GFP-Kos1-expressing clones 1 and 2, respectively (Figure 12a and b) . Importantly, the degree of the inhibitory effect observed for Kos1 on Raf1 and Erk2 activities also correlates with the differential expression of GFP-Kos1 in the two clones (Figure 10b ). However, since the MAP kinase (Erk2) activity is inhibited to a lower extent than Raf1, it is possible that other mitogenic signals may also be involved in regulating MAPK that may not be affected by Kos1.
Discussion
Murine Kos1 is a novel cytoplasmic NRPTK that is a new member of the Ack family (Neet and Hunter, 1996) . The colocalization of murine Kos1 and human Tnk1 to human chromosome 17p13.1 predicts that they are alternately spliced gene products, while their divergence at the C-terminal region indicates that they may function differently. Kos1 also differs structurally from Tnk1 and the Acks by the presence of other putative regulatory domains (Figure 1a ). For example, the presence of an immunoreceptor tyrosine-based activation motif (ITAM) in Kos1 suggests that 'crosstalk' with other NRPTKs or adaptor molecules, such as Src, Syk and STAMs, may occur (Isakov et al., 1995; Pandey et al., 2000; Sada et al., 2001) . However, unlike Kos1, both Tnk1 and the Acks contain an SH3 domain while only the Acks, with the exception of Drosophila melanogaster Ack (D-Ack; Sem et al., 2002) , possess a CRIB motif that binds the GTP-bound form of Cdc42 (Hoehn et al., 1996; Manser et al., 1993) . Since both Ack1 (Teo et al., 2001) and Ack 2 (Lin et al., 2002; ) possess endocytic activity, the presence of a putative endocytic motif in Kos1 (Figure 1a ) and Tnk1 (Hoehn et al., 1996) suggests that they may also play a role in endocytosis. While the Acks are predominantly expressed in the brain and skeletal muscle (Manser et al., 1993; Yang and Cerione, 1997) , and Tnk1 is expressed mainly in the fetal brain, liver, lung and kidney, but not in the corresponding adult tissues (Hohen et al., 1996) , Kos1 is ubiquitiously expressed in both fetal and adult tissues. Further, while the role of Tnk1 appears to be restricted to early (fetal) development, Kos1 expression is both developmentally regulated and can be upregulated by stress in adult tissues in association with growth inhibition and apoptosis (Figures 2-4) .
Kos1 is upregulated in both murine ES cells during embryoid body formation in vitro and in developing embryos in vivo, suggesting a role in cell development. Furthermore, the upregulation of Kos1 following IL3 withdrawal from factor-dependent cells provided a potential clue to Kos1's function as a potential negative regulator of cell growth. Stable, relatively low-level expression of exogenous Kos1 or kinase-dead Kos1(CN) in NIH 3T3 cells indicated that Kos1 can function as an inhibitor of growth while the kinase-dead form stimulated growth (Figure 8 ). Thus, Kos1 may play a functional role in maintaining homeostatic cell growth and its autotyrosine kinase activity is required. The point mutation introduced at the predicted ATP-binding site of Kos1 (K148A) to create the kinase-dead Kos1(CN) was found to impart a dominant negative growth phenotype on cells expressing this mutant, enabling the cells to proliferate at a significantly faster rate and support anchorage-independent growth in soft agar. These results also indicate that inactivation of Kos1's catalytic activity may play a role in oncogenesis and Kos1 may have potential tumor suppressor properties. Interestingly, Ack2 is also a negative regulator of cell growth . However, unlike Kos1(CN), the kinase-dead version of Ack2 also inhibits cell growth, suggesting that the intrinsic protein-protein interacting capacity of Ack 2 rather than its autotyrosine kinase activity is responsible for the growth inhibitory effect . This feature distinguishes Kos1 and Ack2 and indicates that the mechanism(s) by which these two related NRPTK function to regulate growth may differ.
Kos1 expression inhibits cell growth by a mechanism that may indirectly involve suppression of the RasRaf1-MAPK pathway. In this regard, Kos1 may mimic Ark1, an Ack-related kinase that is expressed in Caenorhabiditis elegans and inhibits cell viability (Hopper et al., 2000) . Mechanistically, Ark1 also indirectly suppresses Ras signaling by inhibiting Sem5, a mammalian homolog of Grb2 and upstream activator of Ras activity (Egan et al., 1993; Hopper et al., 2000) . Therefore, our findings with Kos1 would support a functional role for the Ack family members in negatively regulating growth by, at least in part, inhibiting Ras signaling, albeit by different mechanism(s). While the mechanism by which Kos1 may inhibit Ras activity is not yet clear, it may, at least in part, function by inducing the expression of Rap1A, a known suppressor of oncogenic Ras (Figure 11b ). Interestingly, both Rap1A and Ras possess identical effector domains (i.e. aa 32-40) and can compete for and bind to Raf1 directly to affect its activity. Ras activates Raf1 and Rap1A prevents the activation of Raf1 (Bos, 1998; Okada et al., 1998; Schmitt and Stork, 2001 ). Our preliminary data provide a possible clue to how Kos1 may regulate Ras, although additional studies will be required to test this. Therefore, induction of Rap1A by forced expression of Kos1 may potentially lead to the sequestration of Raf1 with the resultant inability of Raf1 to be activated. This could, in turn, result in the inhibition of the Raf1-MAPK pathway (Figure 12) . However, other possible mechanism(s) by which Kos1 may indirectly suppress Ras/oncogenic Ras could potentially involve the GAPs, GEFs or other cellular regulators of Ras. Therefore, additional studies will be required to address these possibilities.
In conclusion, we have discovered Kos1, a novel NRPTK that is the newest member of the Ack family of NRPTKs. Functional analysis indicates that Kos1 may Kos1 (kinase of stem cells), a negative regulator of cell growth K Hoare et al inhibit cell growth by a mechanism involving indirect inhibition of Ras activity and down-regulation of Ras-RAF1-MAPK growth pathway.
Materials and methods
Embryonic stem (ES) cell culture and embryoid body preparation D3ES cells were maintained on gelatin-coated tissue culture dishes in ES media, [80% Dulbecco's modified Eagle's media supplemented with 20% fetal calf serum, 4 mmol/l l-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.1 mm/l nonessential amino acids (GIBCO, Grand Island, NY, USA), 0.1 mmol/l 2-mercaptoethanol and 10 ng/ml of human leukemia inhibitory factor (LIF)]. The medium was changed daily and the cells were passaged every 3 days. Single cell suspensions containing 1-2 Â 10 6 cells were seeded on a 60 mm dish. For embryoid body preparation, single cell suspensions were cultured at 1-2 Â 10 3 cells/ml, in bacterial grade Petri dishes containing 0.9% methyl cellulose in ES growth medium in the absence of LIF. Cells were maintained for 3-15 days in a humidified 5% CO 2 incubator at 371C (Wiles and Keller, 1991) .
RNA isolation
RNA was extracted from D3ES cells following LIF withdrawal after 3 days by the acid guanidinium/phenol/chloroform method (Chomczynski and Sacchi, 1987) . RNA was treated with DNase (GIBCO BRL, Gaithersburg, MD, USA), phenol : chloroform extracted, ethanol precipitated and resuspended in sterile DEPC-treated dH 2 O. PolyA + RNA was purified from the total RNA using Poly (A) Pure mRNA isolation Kit (Ambion Inc, TX, USA).
Degenerate PCR
cDNA synthesis was carried out at 371C, by annealing 1 mg purified polyA + RNA with random primers at 581C and performing a reverse transcription using MMLV reverse transcriptase (GIBCO BRL, Gaithersburg, MD, USA) at 371C. Degenerate primers that targeted the conserved aminoacid sequences VHRDLA [PTK1: (Hanks et al., 1988) were made as described by Wilks (1989) . An aliquot, 5 ml of the cDNA, was amplified using the degenerate primers by denaturing at 941C for 1 min, annealing at 371C for 1.5 min and extending at 721C for 2 min in 35 cycles. Extension at 721C was carried out for 10 min more after the last cycle. PCR products were separated on agarose gel and the band corresponding to 210 bp was purified using Gene Clean (Bio 101, Vista, CA, USA). Not1 and Sal1 sites in the primers allowed subcloning these fragments in pBluescript KS(-) vector (Stratagene, La Jolla, CA, USA).
DNA sequencing
DNA sequencing was performed using a cycle sequencing protocol, using ampli Taq DNA polymerase (Perkin Elmer Corp., Norwalk, CT, USA). Sequence analysis was carried out using a model 373 DNA sequence analyzer (Perkin-Elmer, Applied Biosystems, CA, USA). DNA sequences were compared to known sequences in Genbank (NIH, Bethesda, MD, USA).
5
0 and 3 0 RACE 5 0 and 3 0 RACE were performed essentially as described (Frohman, 1993) . Briefly, for 5 0 RACE, poly-A + RNA from d3 D3ES cells, following LIF withdrawal was annealed with Kos1 oligonucleotide (1095-3 0 -ATCAGAGGCAGACGAGAAGG) at 581C and reverse transcribed using MMLV reverse transcriptase at 371C for 2 h. The cDNA products were tailed with poly (A) using terminal nucleotidyl transferase (TdT) according to the manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN, USA). An aliquot (5 ml) from the cDNA pool was amplified using 25 pmol Kos1 oligonucleotide (1086-3 0 -AGACGAGAAGGCTCCCTG) and 2 pmol of oligonucleotide RACE #1 (GATGGATC CTGCA-GAAGC (T) 17 ) in a reaction buffer (67 mm Tris-HCl, pH 9.0, 6.7 mm MgCl 2 , 170 mg/ml BSA, 16.6 mm (NH 4 ) 2 SO 4 ) containing 10% DMSO (Sigma Chemical, St Louis, MO, USA) and 1.5 mm deoxynucleotidetriphosphates (dNTPs). A second round of amplification was carried out using 25 pmol Kos1 oligonucleotide (1086-3 0 -AGACGAGAAGGCTCCCTG) and 25 pmol of oligonucleotide RACE #2 (GATGGAT CCTGCAGAAGC). In both cases, samples were heated to 971C for 5 min, cooled to 751C before adding Taq polymerase (GIBCO BRL, Gaithersburg, MD, USA). Products were annealed at 501C for 2 min, extended at 721C for 45 min, followed with 35 cycles of 941C for 1 min, 501C for 1 min, 721C for 3 min, with a final 15 min extension at 721C. PCR products were then diluted and amplified with Kos1 oligonucleotides (1064-3 0 -AGGCTC TCTGGGGCTCACAC) and RACE #2 as above, excluding the initial annealing and extension steps. RACE products were cloned into the TA vector (Invitrogen, San Diego, CA, USA), and colonies containing 5 0 Kos1 sequences were identified by hybridizing with internal, oligonucleotide Kos1 (955-5 0 -ATTAAGGTGGC GGATTTT-GG), according to established protocols (Sambrook et al., 1989) . For 3 0 RACE, mRNA from d3 ES cells following LIF withdrawal was reverse transcribed with oligo-(dT) using Superscript II (GIBCO BRL, Gaithersburg, MD, USA) at 421C for 2 h. cDNA was amplified with 25 pmol of oligonucleotides RACE #1 and Kos1:955 (5 0 ) as in the first round of 5 0 -RACE. The second round of PCR used 25 pmol of oligonucleotides RACE #2 and Kos1 (1044-5 0 -CTGGTGTGCCCCAGA-GAG) as described for 5 0 RACE. 3 0 RACE products were cloned into the TA vector and transformants containing 3 0 Kos1 sequences were identified using Kos1 oligonucleotide 1086 (3 0 ). PCR was carried out using overlapping templates generated from the 5 0 and 3 0 RACE products using high-fidelity Taq polymerase (Boehringer Mannheim, Indianapolis, IN, USA) and the primer pair Kos1:181 (5 0 ) (ATGCTCCCTGAAGC-CAGTTC) and Kos1:1488 (3 0 ) (GCCTCAGGTTCTGCAC TTC C) in order to obtain a 1.3 kb Kos1 cDNA ORF (Higuchi, 1989) . This ORF was cloned into the TA vector for sequencing as described.
Identification of Kos gene
Kos genomic DNA (B8.5 kb) was isolated by screening a 129/ Sv murine bacterial artificial chromosome (BAC) library using the 1.3 kb Kos1 cDNA (Genome System Inc., St Louis, MO, USA). Two BAC clones were found to contain Kos gene, which was confirmed by restriction digestion analysis and Southern analysis using full-length Kos1 cDNA, 230 bp Nterminal Kos1, 153 bp C-terminal unique Kos1 probes. Kos genomic DNA was subcloned in pZero vector (Invitrogen, San Diego, CA, USA) by utilizing the unique Sph1 site and was sequenced in both directions.
Northern analysis and ribonuclease protection assay (RPA)
Mouse polyA + embryo blots (Clontech, Palo Alto, CA, USA) were hybridized at 651C with 32 P-labeled 1.3 kb Kos1 cDNA, 230 bp N-terminal and 153 bp unique C-terminal Kos1 probes, according to the supplier's instructions. RPA was carried out using the RPA Kit (II) (Ambion Inc, Austin, TX, USA). A 230 bp N-terminal, a 153 bp unique C-terminal Kos1 and a 125 bp actin-specific cDNA fragments were used to prepare the 280 bp and 200 bp Kos1 probes, and 150 bp actin cDNA control probe, respectively, according to the manufacturer's protocol. In total, 1 mg of PolyA + RNAs from d3 D3ES cells and from various other mouse tissues were hybridized with the 32 P-labeled probes prepared and the protected fragments analysed, according to the manufacturer's protocol.
Immunoblot analysis
Cell extracts were prepared using a modified RIPA lysis buffer (50 mm HEPES (pH 7.5), 150 mm NaCl, 1% Triton X-100, 2 mm EDTA, 2 mm EGTA, 50 mm sodium b-glycerophosphate, 5 mm sodium pyrophosphate, 50 mm NaF, 1 mm sodium orthovanadate, 1 mm DTT, 1 mm phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin and 10 mg/ml aprotinin). Protein was estimated using the Bradford reagent (BioRad Laboratories, CA, USA), according to the manufacturer's protocol. Whole cell lysates (50-100 mg) of each sample was resolved on 8 or 10% polyacrylamide-SDS gels and electroblotted onto a nitrocellulose membrane for Western analysis by standard procedure (Ito et al., 1997) . Western analysis of mouse parenchymal tissue blot was performed (RNWAY Laboratories Inc., Seoul, Korea). A rabbit polyclonal a-Kos antibody was raised against a Kos1 peptide located in the unique Cterminal extra catalytic domain (aa 380-393) and the antiserum was used at (1 : 1000) dilution. Peptide competition was undertaken by incubating excess peptide directly with the antiserum by gentle rocking for 30 min at room temperature prior to using for Western analysis. Other antibodies used were obtained commercially, including rabbit polyclonal anti-Raf1 (Upstate Biotechnology, Lake Placid, NY, USA); anti-GST, anti-Ras anti-Py20 and anti-Rap1A (Transduction Laboratories, Lexington, KY, USA); rabbit polyclonal anti-Erk2, anti-Actin and mouse monoclonal antiphospho Erks (Santa Cruz Biotechnology, CA, USA) and mouse anti-GFP (Clontech, Palo Alto, CA, USA). Protein bands were visualized using enhanced chemiluminescence detection system (Amersham-Pharmacia Biotech, Arlington Heights, IL, USA).
Mutagenesis and subcloning
Catalytically null Kos1 was generated by replacing 148 lysine (K) with alanine (A) at the ATP-binding domain of PTKs (Figure 1 ; Hanks and Hunter, 1995; Hanks et al., 1988) . PCR was carried out on the Kos1 cDNA template using two primer pairs (1) Kos1: 181 (AGGATCCATGCTCCCTGAAGC-CAGTTC)/Kos1: 632 (ACGGAGGGA CTTGACCGCCAC) and (2) Kos1: 612 (GTGGCGGTCAAGTCCCTCCGT)/ Kos1: 1482 (ACTGCAGGGGTTCTGCACTTCCTG-CAGG). The PCR products were purified and equimolar ratio of the two overlapping PCR products were used as template, to carry out a PCR (Higuchi, 1989) , using the primer pair Kos1:181 (AGGATCCATGCTCCCT GAAGC-CAGTTC) and Kos1: 1482 (ACTGCAGGGGTTCTG-CACTTCCTGCAGG). The 1.3 kb PCR product was purified using Qiaex II (Qiagen Inc, CA, USA) and subcloned into the shuttle vector pZero at the Sma1 site. The, pZero Kos1(CN) cDNA was sequenced to confirm the mutation. The Kos1(CN) cDNA was excised from the pZero plasmid using BamH1, purified and subcloned at the BamH1 site of the plasmid pC1EGFP (Clontech) to obtain GFP-Kos1(CN). The wt-Kos1 cDNA was subcloned directionally into pC1EGFP at the BglII and Xho1 sites to obtain GFP-Kos1. The plasmid pC1EGFP-Kos1 cDNA was digested with EcoR1, purified and religated to generate a truncated Kos1 (GFP-DKos), lacking 153 bp of the unique C-terminal of Kos1. The molecular weights of GFP-DKos, GFP-Kos1 and GFP-Kos1(CN) are predicted to be 68, 74 and 78 kDa, respectively.
Cell culture, DNA transfection and establishment of stable clones
The murine IL3-dependent NFS/N1.H7 cells were cultured in the presence of 10% WEHI condition media, in RPMI1640 containing 10% fetal bovine serum (Ito et al., 1997) . The cells were grown in the absence of IL3 for various time points by culturing the cells in serum-free condition in RPMI 1640, supplemented with 5% BSA. Viability was determined by trypan blue exclusion assay. M1, P1ER, REH, CEM, K562, NCI-H82 and U937 cells were cultured in RPMI 1640 containing 10% fetal bovine serum. NIH 3T3 and Cos7 cells were cultured in DMEM containing 10% fetal bovine/calf serum.
NCI-H82 cells stably expressing Ha-Ras(G12V), obtained from Dr L Xiao (University of Florida), were transfected with GFP-Kos1 using lipofectamine (GIBCO BRL, Gaithersburg, MD, USA) according to the manufacturer's protocol. At 48 h of post-transfection, cells were challenged with 1.0 mg/ml G418 (GIBCO BRL, Gaithersburg, MD, USA) to isolate resistant cells. Cells emitting green fluorescence were sorted by fluorescence-activated cell sorting (FACS) as a single cell culture in a 96-well plate. Out of 96 clones tested for GFPKos1 expression by Western blotting using mouse a-GFP antibody (at 1 : 2000 dilution; Clontech), only two clones were isolated that expressed the 74-kDa GFP-Kos1. The remaining 94 clones expressed GFP, indicating termination of translation of Kos1 ORF.
Soft agar assay and growth studies
Soft agar assays were carried out in 30 mm tissue culture dishes (Lloyd et al., 1989) . To determine the ability of different cell lines to grow on soft agar, cells were seeded in 0.4% agarose in RPMI1640/DMEM plus 10% fetal bovine serum (FBS), and overlaid on 0.8% agarose in the same medium. For growth curves, cells were grown in RPMI 1640 or DMEM containing 10 or 0.5% FBS in triplicates. At various time points, the cell number was determined by trypan blue exclusion.
Subcellular fractionation of M1 cells
Subcellular fractionation of M1 cells was performed to obtain organelles and cytosol (Wang et al., 1996) . In brief, cells were allowed to swell in ice-cold hypotonic HEPES buffer (10 mm HEPES pH 7.4, 5 mm MgCl 2 , 40 mm KCl 2 , 1 mm PMSF, 10 mg aprotinin and 10 mg of leupeptin) for 30 min, sheared by repeated aspiration through a 25-guage needle, and centrifuged at 200g to pellet the nuclei. The supernatant was centrifuged at 10 000g to pellet the heavy membrane fraction. The resulting supernatant was centrifuged at 150 000g to pellet the light membrane fraction. The resulting supernatant contains the cytosolic fractions. In all, 50 mg of total protein from each fraction was subjected to 10% SDS-PAGE and analysed by Western blotting.
Immunofluorescence
Immunofluorescence microscopy was performed on cells using a Zeis Axioplan II microscope. Photomicrographs were taken using a Micromax CCD camera (Princeton Instrument) and the images were processed using Adobe Photoshop (Adobe Systems, Mountain View, CA, USA). Cos7 cells expressing GFP and the GFP-Kos1 were incubated at 100 mg/ml with Hoechst 33342 (Sigma Chemicals, St Louis, MO, USA) in PBS for 15 min. After washing with PBS, the cells were visualized for GFP and Hoechst 33342 fluorescence.
Tyrosine kinase activity assay
Cos7 cells (2 Â 10 5 cells) were grown in 60 mm tissue culture dishes. Tyrosine phosphorylation in vivo was determined by transfecting cells with pC1EGFP carrying DKos, wt-Kos1 and Kos1(CN), and were also cotransfected in a 1 : 1 mix of GFPKos1(CN) with GFP-Kos1 or GFP-DKos using lipofectamine, according to the manufacturer's protocol (GIBCO BRL, Gaithersburg, MD, USA). After 48 h of transfection, the cells were washed with phosphate-free RPMI 1640 (GIBCO BRL, Gaithersburg, MD, USA) and metabolically labeled with 32 P orthophosphoric acid (ICN, Inc., CA, USA) at a final concentration of 0.25 mCi/ml in 4 ml of phosphate-free RPMI1640 medium for 3 h. Labeled cells were washed 3 times with ice-cold Tris-buffered saline (TBS) and lysed with modified RIPA buffer. GFP and GFP-fusion proteins in the clarified supernatants were immunoprecipitated with a rabbit a-GFP antibody, resolved and analysed by Western blotting.
Measurement of Ras-bound guanine nucleotides
Ras-bound guanine nucleotides were quantitated according to the method of Satoh and Kaziro (1995) . In brief, NCI-H82 cells expressing either Ha-Ras(G12V)/GFP or Ras(G12V)/ GFP-Kos1 were grown in RPMI 1640 containing 0.5% FBS for 24 h to effect serum starvation. The cells (5 Â 10 7 cell/assay) were subsequently metabolically labeled with 32 P orthophosphosphoric acid (ICN, Inc., CA, USA) for 4 h. Cells were washed 3 times with ice-cold TBS and finally lysed with RIPA as mentioned above. Duplicate supernatant aliquots containing 800 mg of protein were made. One set (T) received 2 mg of anti-Ras rat monoclonal antibody Y13-259 (Santa Cruz Biotechnology, CA, USA) while no antibody was added to the other and served as the mock control (C). The supernatants were incubated at 41C for 60 min with gentle rocking followed by centrifugation at 15 000g for 5 min at 41C. The supernatants from both T and C were transferred to new Eppendorph tubes containing 25 ml of protein G plus-agarose (GIBCO BRL, Gaithersburg, MD, USA) and incubated as before for an additional hour. The beads were washed 8 times with 1 ml of wash buffer (50 mm HEPES pH 7.5, 500 mm NaCl, 5 mm MgCl 2 , 0.1% Triton X-100 and 0.005% SDS). The immunoprotein G-agarose/protein G-agarose complex was dissociated by incubating at 681C for 20 min in 20 ml of elution buffer (2 mm EDTA, 2 mm DTT, 0.2 % SDS, 0.5 mm GDP and 0.5 mm GTP). Finally, after centrifugation at 15 000g for 5 min at 41C, the supernatants were collected and spotted (10 ml each) onto a PEI-cellulose plate (JT Baker, NJ, USA) containing a fluorescent indicator for identifying the guanyl nucleotides that fluoresce under UV light, and ascending chromatography was carried out in 0.75 m KH 2 PO 4 (pH 3.4). The plate was dried and exposed to Instant Imager (Packard Instrument, Meriden, CT, USA) for quantitation.
Ras activation assay
The in vivo Ras activation assay was carried out on Cos7 cells using a nonradioactive kit according to the manufacturer's protocol (Upstate Biotechnology, Lake Placid, NY, USA). Briefly, Cos7 cells (2 Â 10 5 cells) in 60 mm tissue culture dishes were cotransfected with 1 mg each of plasmids: (1) pCDNA3-wtRas and pC1EGFP (GFP), (2) pCDNA3-wtRas and pC1EGFP-DKos (GFP-DKos), (3) pCDNA3-wtRas and pC1EGFP-wtKos1 (GFP-Kos1) and (4) pCDNA3-wtRas and pC1EGFP-Kos1(CN) (GFP-Kos1(CN)). Cells were also transfected with 2 mg of pC1EGFP (vector alone). After 48 h of transfection, cells were lysed with the 1 Â lysis/wash buffer according to the manufacturer's protocol. In total, of 500 mg of protein from each clarified cell lysate was precleared using glutathione-agarose for 30 minutes at 41C followed by incubation with Raf1 RBD-agarose (ras binding domain) for 30 min at 41C. The agarose beads were washed, resolved on 14% SDS-PAGE gel and protein bands were transferred on to nitrocellulose filter for Western analysis using a-Ras antibody. The bands were quantitated by densitometry.
Immunocomplex kinase assay for Raf1 and Erk2
NCI-H82 cells stably expressing oncogenic Ha-Ras(G12V) and GFP-Kos1 or GFP were grown in RPMI containing 0.5% FBS for 24 h and lysed in modified RIPA buffer. From the clarified cell lysate (500 mg protein) endogenous Raf1 was immunoprecipitated using 5 mg sheep a-Raf1 antibody (Upstate Biotechnology, Lake Placid, NY, USA). Erk2 was immunoprecipitated from clarified cell lysate (50 mg protein) using 1 mg rabbit a-Erk2 antibody (Santa Cruz Biotechnology, CA, USA). Immunoprecipitation was carried out using 20 ml of protein A-agarose (Life Technologies, Gaithersburg, MD, USA). The immunocomplex was washed twice with lysis buffer and kinase assay buffer (25 mm HEPES (pH 7.5), 20 mm MgCl 2 , 0.1 mm EGTA, 50 mm sodium b-glycerophosphate, 0.1 mm sodium orthovanadate, 1 mm DTT and 1 mm okadaic acid). Kinase reactions were carried out by incubating the immunoprecipitates with the respective substrates in 30 ml of kinase assay buffer supplemented with 20 mm ATP and 5 mCi [g 32 Pi]ATP at room temperature for 30 min. In total, 10 mg of MBP and 0.4 mg of GST-MEK1 (Upstate Biotechnology, Lake Placid, NY, USA) were used as substrates for determining the Erk2 and Raf1 activities, respectively. The kinase reactions were terminated using the PAGE sample buffer, protein bands were resolved on a 10 or 12% SDS-PAGE gels and transferred on to nitrocellulose filter. Phospho-GST-MEK1 and phospho-MBP were first analysed by Instant Imager (Packard Instrument, Meriden, CT, USA) followed by Western blot analysis using a-GST, a-Raf1 and a-Erk2 antibodies.
